These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Costs for traditional meds static while specialty drug costs soar. Manag Care; 2012 Jun; 21(6):47. PubMed ID: 22792564 [No Abstract] [Full Text] [Related]
8. A few specialty drug prices fall--all generics. Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766 [No Abstract] [Full Text] [Related]
9. Managed care outlook. Specialty drugs increasingly used to treat chronic conditions. Manag Care; 2007 Aug; 16(8):53. PubMed ID: 17886543 [No Abstract] [Full Text] [Related]
10. Trends in economic consequences of rheumatoid arthritis over two subsequent years. Verstappen SM; Jacobs JW; Kruize AA; Ehrlich JC; van Albada-Kuipers GA; Verkleij H; Buskens E; Bijlsma JW Rheumatology (Oxford); 2007 Jun; 46(6):968-74. PubMed ID: 17337750 [TBL] [Abstract][Full Text] [Related]
11. Rituximab (Rituxan) for rheumatoid arthritis. Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143 [No Abstract] [Full Text] [Related]
12. Plans struggle for control of specialty pharma costs. Carroll J Manag Care; 2005 Sep; 14(9):41-2, 45-8. PubMed ID: 16238258 [No Abstract] [Full Text] [Related]
13. Drug utilization still growing, though price increases moderate for common nonspecialty drugs. Capitation Rates Data; 2007 Aug; 12(8):94-6. PubMed ID: 17703704 [No Abstract] [Full Text] [Related]
14. American Society of Clinical Oncology guidance statement: the cost of cancer care. Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE; J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533 [TBL] [Abstract][Full Text] [Related]
15. Rising drug costs prompt new uses for old pills. Opar A Nat Med; 2006 Dec; 12(12):1333. PubMed ID: 17151672 [No Abstract] [Full Text] [Related]
16. Pharmacy cost increases below medical for the first time in four years. Manag Care; 2005 Dec; 14(12):59. PubMed ID: 16405250 [No Abstract] [Full Text] [Related]
17. The burden of rheumatoid arthritis and access to treatment: determinants of access. Lundqvist J; Kastäng F; Kobelt G; Jönsson B Eur J Health Econ; 2008 Jan; 8 Suppl 2():S87-93. PubMed ID: 18157560 [TBL] [Abstract][Full Text] [Related]
18. The pharmacoeconomics of newer therapeutics for rheumatic diseases. Kavanaugh A Rheum Dis Clin North Am; 2006 Feb; 32(1):45-56, viii. PubMed ID: 16504820 [TBL] [Abstract][Full Text] [Related]
19. Oncology and specialty drug management in managed care. Navarro RP Manag Care Interface; 2007 Sep; 20(9):25-6, 29. PubMed ID: 18161387 [No Abstract] [Full Text] [Related]
20. Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis. Oliveira B; Arkfeld DG; Weitz IC; Shinada S; Ehresmann G J Clin Rheumatol; 2007 Apr; 13(2):89-91. PubMed ID: 17414538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]